Home›ETFs & Funds›Fund Industry›Eli Lilly sues pharmacies and peptide vendors over com…

Eli Lilly sues pharmacies and peptide vendors over compounded retatrutide

The lawsuit targets third parties selling peptide versions of retatrutide that consumers use for weight-loss and related wellness purposes, including through compounded offerings.

Reported · Written up by our desk · Fund Industry

Eli Lilly has filed legal action against pharmacies and peptide vendors over the sale of retatrutide, a next-generation weight-loss drug, as some consumers seek access through alternative channels.

According to MarketWatch, some Americans have turned to medical spas and pharmacies that sell peptides for health and wellness benefits, using compounded versions of retatrutide rather than the company’s standard drug route.

MarketWatch reports the dispute centers on the availability of compounded retatrutide linked to peptide sales, raising issues for the company as demand for the weight-loss therapy continues to draw interest.

More like this

Sources